Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
MDXG

MDXG - MiMedx Group, Inc. Stock Price, Fair Value and News

6.90USD-0.26 (-3.63%)Market Closed

Market Summary

MDXG
USD6.90-0.26
Market Closed
-3.63%

MDXG Alerts

  • Big jump in Earnings (Y/Y)

MDXG Stock Price

View Fullscreen

MDXG RSI Chart

MDXG Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

14.05

Price/Sales (Trailing)

3.04

EV/EBITDA

23.89

Price/Free Cashflow

29.25

MDXG Price/Sales (Trailing)

MDXG Profitability

EBT Margin

13.59%

Return on Equity

46.54%

Return on Assets

32.69%

Free Cashflow Yield

3.42%

MDXG Fundamentals

MDXG Revenue

Revenue (TTM)

334.5M

Rev. Growth (Yr)

18.18%

Rev. Growth (Qtr)

-2.44%

MDXG Earnings

Earnings (TTM)

72.5M

Earnings Growth (Yr)

285.85%

Earnings Growth (Qtr)

-82.68%

Breaking Down MDXG Revenue

Last 7 days

-3.5%

Last 30 days

-12.4%

Last 90 days

-12.4%

Trailing 12 Months

20.8%

How does MDXG drawdown profile look like?

MDXG Financial Health

Current Ratio

3.29

Debt/Equity

0.12

Debt/Cashflow

1.99

MDXG Investor Care

Shares Dilution (1Y)

27.68%

Diluted EPS (TTM)

0.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024334.5M000
2023280.6M295.0M309.0M321.5M
2022240.9M239.7M244.3M267.8M
2021246.5M261.0M259.8M242.0M
2020294.4M280.6M256.1M248.2M
2019341.5M313.5M315.4M299.3M
2018336.5M351.4M354.4M359.1M
2017260.4M283.6M303.2M321.1M
2016199.9M211.6M227.0M245.0M
2015139.4M159.5M175.0M187.3M
201467.2M79.2M96.6M118.2M
201334.9M43.5M51.7M59.2M
201210.4M13.4M19.2M27.1M
20112.5M4.3M6.0M7.8M
2010000788.9K
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of MiMedx Group, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 05, 2024
puhy dorothy e
acquired
210,453
7.26
28,988
-
Jun 05, 2024
bierman james l
acquired
168,359
7.26
23,190
-
Jun 05, 2024
newton todd
acquired
168,359
7.26
23,190
-
Jun 05, 2024
olson tiffany
acquired
210,453
7.26
28,988
-
Jun 05, 2024
laurencin cato t
acquired
168,359
7.26
23,190
-
Jun 05, 2024
behrens m kathleen
acquired
168,359
7.26
23,190
-
Jun 05, 2024
hawkins william a
acquired
168,359
7.26
23,190
-
May 08, 2024
hulse william frank iv
sold (taxes)
-64,051
7.2
-8,896
general counsel and cao
Apr 23, 2024
hulse william frank iv
sold (taxes)
-57,913
6.51
-8,896
general counsel and cao
Apr 08, 2024
hulse william frank iv
sold (taxes)
-61,382
6.9
-8,896
general counsel and cao

1–10 of 50

Which funds bought or sold MDXG recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
-6,000
39,000
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-4.64
-174,682
898,898
-%
May 16, 2024
COMERICA BANK
reduced
-8.18
-1,538
6,399
-%
May 16, 2024
SkyView Investment Advisors, LLC
new
-
77,000
77,000
0.01%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-5.05
-107,889
540,548
-%
May 15, 2024
VOLORIDGE INVESTMENT MANAGEMENT, LLC
reduced
-61.09
-444,994
230,892
-%
May 15, 2024
Bridgefront Capital, LLC
new
-
130,977
130,977
0.10%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-97.03
-133,996
3,588
-%
May 15, 2024
Man Group plc
reduced
-49.63
-218,343
173,150
-%
May 15, 2024
GOLDMAN SACHS GROUP INC
added
28.78
556,101
4,811,630
-%

1–10 of 49

Are Funds Buying or Selling MDXG?

Are funds buying MDXG calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MDXG
No. of Funds

Unveiling MiMedx Group, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
5.64%
6,567,254
SC 13G/A
Jan 25, 2024
blackrock inc.
8.2%
9,533,518
SC 13G/A
Dec 27, 2023
falcon fund 2 holding company, l.p.
19.3%
28,195,249
SC 13D/A
Feb 09, 2023
vanguard group inc
5.36%
6,094,595
SC 13G
Feb 01, 2023
blackrock inc.
6.8%
7,781,521
SC 13G/A
Jun 15, 2022
prescience investment group llc
5.0%
5,719,888
SC 13G
May 09, 2022
prescience investment group llc
5.0%
5,719,888
SC 13D/A
Apr 28, 2022
prescience investment group llc
5.0%
5,719,888
SC 13D
Feb 08, 2022
prescience investment group llc
5.5%
6,119,888
SC 13G/A
Feb 04, 2022
blackrock inc.
6.5%
7,276,373
SC 13G

Recent SEC filings of MiMedx Group, Inc.

View All Filings
Date Filed Form Type Document
Jun 07, 2024
8-K
Current Report
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
May 09, 2024
4
Insider Trading
Apr 30, 2024
10-Q
Quarterly Report

Peers (Alternatives to MiMedx Group, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.95
10.1
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.84
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.89
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.85
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.07
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

MiMedx Group, Inc. News

Latest updates
MarketBeat04 Jun 202402:22 am
Simply Wall St14 May 202407:00 am
Seeking Alpha30 Apr 202407:00 am
Yahoo Finance3 months ago

MiMedx Group, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-2.4%84,709,00086,832,00081,712,00081,257,00071,676,00074,375,00067,689,00066,883,00058,894,00050,813,00063,074,00068,165,00059,967,00068,548,00064,303,00053,647,00061,736,00076,400,00088,863,00067,437,00066,555,000
Gross Profit-1.7%71,722,00072,990,00066,922,00067,674,00059,257,00060,006,00055,501,00055,060,00048,958,00043,715,00052,945,00055,405,00050,326,00057,730,00054,014,00045,449,00051,711,00063,691,00075,658,00057,688,00059,137,000
  S&GA Expenses1.4%55,129,00054,364,50052,571,00051,925,00052,250,00049,835,00053,475,00055,793,00049,570,00049,554,50046,289,00053,599,00045,404,00048,705,50048,046,00037,329,00046,942,00045,444,00051,258,00050,641,00050,862,000
  R&D Expenses171.1%2,841,000-3,997,0003,175,0008,497,0003,484,000-4,728,0005,953,0005,512,0005,964,000-2,838,0004,368,0004,063,0004,339,0003,434,0003,372,0002,259,0002,650,0002,719,0002,691,0002,828,0002,902,000
EBITDA Margin40.2%0.120.090.04-0.02-0.06-0.08-0.13-0.10-0.06-0.05-0.12-0.18---------
Interest Expenses-6.1%-1,690,000-1,593,500-1,680,000-1,630,000-1,553,000-1,450,000-1,270,000-1,170,000-1,126,000-1,174,000-963,000-1,371,000-1,472,000-1,508,000-1,472,000-2,574,000-2,387,000-2,395,000-2,255,000-269,000211,000
Income Taxes106.3%2,348,000-37,374,500591,000-74,00051,00028,00053,00062,00063,000-107,500301,000-5,00058,000-1,020,00038,00027,000-11,304,000220,000-309,00042,00042,000
Earnings Before Taxes-52.0%11,409,00023,793,0009,125,0001,126,000-1,891,0009,858,000-8,373,000-10,806,000-10,426,00091,500-2,038,000-1,784,000-8,324,000-17,600,000-19,379,000-8,439,000-16,125,000-7,256,00012,070,000-17,168,000-13,231,000
EBT Margin35.9%0.140.100.05-0.01-0.05-0.07-0.12-0.10-0.06-0.05-0.11-0.18---------
Net Income-82.7%9,261,00053,477,0008,534,0001,200,000-4,983,000-414,000-8,426,000-10,868,000-10,489,0002,215,000-2,339,000-1,779,000-8,382,000-16,580,000-19,417,000-8,466,000-4,821,000-7,476,00012,379,000-17,210,000-13,273,000
Net Income Margin19.6%0.220.180.01-0.04-0.09-0.11-0.11-0.09-0.05-0.04-0.11-0.18---------
Free Cashflow-43.5%5,551,0009,830,00012,163,0007,476,000-4,681,000-6,291,000610,000-3,385,000-10,341,000-3,557,0005,783,0001,194,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-7.3%222239189176168171173169174188181187191202213151159167179170107
  Current Assets-15.5%13916415514113213413613113614914214815016117110811612313412357.00
    Cash Equivalents-40.9%48.0082.0081.0069.0061.0066.0073.0073.0076.0087.0091.0085.0085.0096.0011048.0054.0069.0094.0097.0028.00
  Inventory16.3%24.0021.0019.0017.0015.0013.0014.0013.0013.0011.0011.0010.0012.0010.0011.0011.009.009.0012.0015.0016.00
  Net PPE-------------11.0011.0010.0011.0012.0012.0013.0015.0016.00
  Goodwill0%19.0019.0019.0019.0020.0019.0020.0020.0020.0019.0020.0020.0020.0020.0020.0020.0020.0020.0020.0020.0020.00
Liabilities-31.5%66.0096.0095.0097.0094.0097.0010090.0089.0095.0094.0010210711110912812913314014669.00
  Current Liabilities-8.2%42.0046.0044.0044.0041.0044.0046.0037.0037.0042.0042.0051.0055.0059.0057.0064.0064.0067.0073.0078.0064.00
  Long Term Debt-61.6%18.0048.0049.0049.0049.0049.0048.0048.0048.0048.0048.0048.0048.0048.0048.0061.0062.0062.0062.0063.00-
    LT Debt, Current0%1.001.00-------------4.004.004.004.004.00-
    LT Debt, Non Current-61.6%18.0048.0049.0049.0049.0049.0048.0048.0048.0048.0048.0048.0048.0048.0048.0061.0062.0062.0062.0063.00-
Shareholder's Equity9.1%1561431.00--17.95-17.99---0.00----13.0023.0030.0034.0040.0025.0038.00
  Retained Earnings6.9%-124-133-187-195-196-191-191-183-172-161-163-161-159-151-134-115-106-102-94.66-107-89.83
  Additional Paid-In Capital1.4%280276188183179174172169165166162159157159158152150147144136166
Shares Outstanding0.9%148146116116114114113113112110111110---------
Float----760---388---1,381---538---425-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-41.7%5,97810,25712,7917,775-4,048-5,624959-3,005-10,223-3,2326,3301,599-6,679-10,267-4,618-3,097-12,281-23,122-3,1602,130-15,260
  Share Based Compensation-1.1%4,3404,3874,3884,0603,9045302,3724,4283,9983,0413,8114,0603,2443,9053,6694,4343,3492,8652,6863,4993,014
Cashflow From Investing-1152.4%-6,024-481-649-348-677-1,709-374-429-148-314-580-422-2,079-2,273-710-486-1,086-7932,060-330-433
Cashflow From Financing-274.4%-33,467-8,9403704.00-4.0066.00130260-1,03622.00-150-916-2,308-1,24366,734-1,753-2,177-1,138-1,70766,748-1,044
  Buy Backs----------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

MDXG Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Net sales$ 84,709$ 71,676
Cost of sales12,98712,419
Gross profit71,72259,257
Operating expenses:  
Selling, general and administrative55,12952,250
Research and development2,8413,484
Investigation, restatement and related3113,673
Amortization of intangible assets189190
Impairment of intangible assets540
Operating income (loss)13,198(340)
Other expense, net  
Interest expense, net(1,690)(1,553)
Other (expense) income, net(99)2
Income (loss) from continuing operations before income tax11,409(1,891)
Income tax expense from continuing operations(2,348)(51)
Net income (loss) from continuing operations9,061(1,942)
Income (loss) from discontinued operations, net of tax200(3,041)
Net income (loss)9,261(4,983)
Net income (loss) from continuing operations available to common stockholders$ 9,061$ (3,626)
Basic net income (loss) per common share:  
Continuing operations - basic (in dollars per share)$ 0.06$ (0.03)
Discontinued operations - basic (in dollars per share)0(0.03)
Basic net income (loss) per common share (in dollars per share)0.06(0.06)
Diluted net income (loss) per common share:  
Continuing operations- diluted(in dollars per share)0.06(0.03)
Discontinued operations- diluted (in dollars per share)0(0.03)
Diluted net (loss) income per common share (in dollars per share)$ 0.06$ (0.06)
Weighted average common shares outstanding - basic (in shares)146,404,587114,398,813
Weighted average shares outstanding - diluted (in shares)150,028,107114,398,813

MDXG Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 48,487$ 82,000
Accounts receivable, net57,01653,871
Inventory24,45421,021
Prepaid expenses6,0955,624
Other current assets2,8011,745
Total current assets138,853164,261
Property and equipment, net7,3406,974
Right of use asset3,4992,132
Deferred tax asset, net38,74740,777
Goodwill19,44119,441
Intangible assets, net12,5505,257
Other assets1,251205
Total assets221,681239,047
Current liabilities:  
Current portion of long term debt1,0001,000
Accounts payable9,6979,048
Accrued compensation17,91322,353
Accrued expenses9,1969,361
Current liabilities of discontinued operations3441,352
Other current liabilities4,0712,894
Total current liabilities42,22146,008
Long term debt, net18,45348,099
Other liabilities5,2762,223
Total liabilities65,95096,330
Commitments and contingencies (Note 12)
Stockholders' equity  
Common stock; $0.001 par value; 250,000,000 shares authorized; 147,528,596 issued and outstanding at March 31, 2024 and 146,227,639 issued and outstanding at December 31, 2023148146
Additional paid-in capital280,000276,249
Accumulated deficit(124,417)(133,678)
Total stockholders' equity155,731142,717
Total liabilities and stockholders’ equity$ 221,681$ 239,047
MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.
 CEO
 WEBSITEmimedx.com
 INDUSTRYBiotechnology
 EMPLOYEES867

MiMedx Group, Inc. Frequently Asked Questions


What is the ticker symbol for MiMedx Group, Inc.? What does MDXG stand for in stocks?

MDXG is the stock ticker symbol of MiMedx Group, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MiMedx Group, Inc. (MDXG)?

As of Thu Jun 13 2024, market cap of MiMedx Group, Inc. is 1.02 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDXG stock?

You can check MDXG's fair value in chart for subscribers.

What is the fair value of MDXG stock?

You can check MDXG's fair value in chart for subscribers. The fair value of MiMedx Group, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MiMedx Group, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MDXG so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MiMedx Group, Inc. a good stock to buy?

The fair value guage provides a quick view whether MDXG is over valued or under valued. Whether MiMedx Group, Inc. is cheap or expensive depends on the assumptions which impact MiMedx Group, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDXG.

What is MiMedx Group, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, MDXG's PE ratio (Price to Earnings) is 14.05 and Price to Sales (PS) ratio is 3.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDXG PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MiMedx Group, Inc.'s stock?

In the past 10 years, MiMedx Group, Inc. has provided 0.011 (multiply by 100 for percentage) rate of return.